Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation July 5, 2019
FDA approves Novartis Piqray® (alpelisib) – the first & only treatment specifically for patients with a PIK3CA mutation in HR+/HER2-Neg advanced breast cancer May 24, 2019